|Publication number||US4474798 A|
|Application number||US 06/488,587|
|Publication date||Oct 2, 1984|
|Filing date||Apr 25, 1983|
|Priority date||Apr 30, 1982|
|Also published as||CA1194801A, CA1194801A1, DE3372066D1, EP0093563A2, EP0093563A3, EP0093563B1|
|Publication number||06488587, 488587, US 4474798 A, US 4474798A, US-A-4474798, US4474798 A, US4474798A|
|Inventors||Toshio Inagi, Masayuki Inoue, Toyojiro Muramatsu|
|Original Assignee||Kowa Co., Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (8), Referenced by (20), Classifications (24), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
1. Field of the Invention
This invention relates to a novel preparation of indomethacin for endermic application.
2. Description of the Prior Art
Indomethacin is an excellent non-steroidal, analgesic and antiphlogistic agent. It can however be hardly dissolved in water nor in various solvents which are generally usable as bases for endermic application. Indomethacin is slightly dissolvable in benzyl alcohol,tetrahydrofuran, dimethylsulfoxide, dimethylformamide and the like. The indomethacin solutions thus dissolved suffer some problems in the formation of a preparation suitable for endermic application, from both viewpoints of the concentration and potency of indomethacin. Therefore, indomethacin has been heretofore administered in the form of an oral preparation.
The present inventors have made many studies of preparations of indomethacin for endermic application and have already succeeded in obtaining an endermically-applicable preparation having excellent absorptivity through the skin by incorporating indomethacin in an alcohol-water system and then forming the resultant mixture into a gelated ointment, as disclosed in Japanese Patent Publication No. 10886/1981. Such gelated ointment has been recently marketed and has been found highly valuable in its clinical application.
The present inventors have conducted continuous research with a view toward developing new dosable forms of the endermically-applicable indomethacin preparation and bases therefor. As a result, it has been discovered that certain types of terpenoids and phenols can enhance the solubiliy and stability of indomethacin in bases and hence permit indomethacin to be incorporated in a variety of bases for endermic application. This discovery has led to the present invention.
This invention provides a pharmaceutical preparation for endermic application, which comprises indomethacin and one or more solubilizers selected from the group consisting of C10 terpenoids and C10 phenols.
Eligible terpenoids having 10 carbon atoms and useful as solubilizers in the practice of the invention include hydrocarbonaceous terpenes such as limonene, pinene, camphene and cymene; alcoholic terpenes such as citronellol, geraniol, nellol, linalol, menthol, terpineol, rosinol, borneol and iso-borneol; and ketone-type terpenes such as menthone and camphor. On the other hand, eligible phenols having 10 carbon atoms include thymol, safrole, iso-safrole, eugenol, iso-eugenol and the like. These solubilizers may be used singly or in combination. The content of such solubilizers when used either alone or in combination may vary depending on the content of indomethacin and the type and amount of a solvent utilized. However, the solubilizers are capable of producing satisfactory results when incorporated in a total amount of 0.3-10% by weight.
Eligible solvents useful in dissolving indomethacin include alcohols such as ethanol and propanol; mixed alcohol-water systems; glycols such as butylene glycol and propylene glycol; vegetable oils such as olive oil and soybean oil; liquid higher fatty acids such as oleic acid, linoleic acid and linolenic acid; higher alcohols such as octyl alcohol and hexadecyl alcohol; hydrocarbons such as paraffin and squalane; esters of C4 -C14 monocarboxylic acids and C1 -C5 alcohols; and diesters of C4 -C10 dicarboxylic acids and C1 -C3 alcohols.
A pharmaceutical preparation for endermic application according to the invention may be produced by dissolving indomethacin together with at least one solubilizer in one or more of the above-described solvents, or by further incorporating the thus formed solution in another base for endermic application. Preferably, indomethacin is added in an amount of 0.1-5% by weight.
Eligible forms of the pharmaceutical preparation for endermic application which are obtainable in such manner include, for example, a liquid preparation, an ointment, a gelated ointment, cream, a plaster and the like.
Since the addition of one or more of these solubilizers in a small amount can significantly increase the solubility and stability of indomethacin in various solvents, the resultant indomethacin solutions may be incorporated in a wide variety of bases for endermic application, thus providing endermically-applicable preparations of various forms. Thus, the solubilizers contemplated by the invention are extremely effectively useful.
The invention will now be described in further detail with reference to certain specific experiment and preparation examples which are provided for illustration purposes only and are not construed to be limiting.
A large excess of indomethacin was added to each of a variety of solvents, followed by addition of one of the solubilizers given in Table 1. The resultant mixture was shaken for 24 hours at 25° C. and then subjected to centrifugal separation. The supernatant was collected. The content of indomethacin in the supernatant was determined by the UV method or the HPLC method and compared with that in a supernatant having no stabilizer added thereto. The results are shown in Tables 1 and 2.
TABLE 1__________________________________________________________________________ Solubilizer None (Weight dissolved) l-Menthol l-Menthol l-MentholSolvent (mg/ml) 3% 5% 10%__________________________________________________________________________100% Ethanol 100 130 140 150 (17.4) 80% Ethanol 100 140 200 270 (8.0) 60% Ethanol 100 160 350 440 (2.4) 50% Ethanol 100 350 x x (0.75)Isopropyl 100 210 x xmyristate (1.3)Octylodecyl 100 190 x xmyristate (0.5)Propanol 100 180 x x (7.5)__________________________________________________________________________ Note: The figures are expressed in terms of percentage to the weight of indomethacin dissolved without any solubilizer added in their corresponding solvents. The symbol x indicates that the solubilizer was not dissolved in the solvent.
TABLE 2__________________________________________________________________________ SolventSolubilizer 100% Ethanol 80% Ethanol 60% Ethanol 50% Ethanol__________________________________________________________________________None (weight dissolved) 100 100 100 100(mg/ml) (17.4) (8.0) (2.4) (0.75)dl-Camphor 3% 120 150 170 270dl-Camphor 5% 160 190 230 400dl-Camphor 10% 200 230 390 xEugenol 3% 140 160 170 xEugenol 5% 400 190 250 xD-limonene 3% 140 170 x xD-limonene 5% 250 200 x x__________________________________________________________________________ Note: The figures and the symbol x have the same significance as given in Table 1.
Preparation Example 1: (Ointment)
______________________________________Indomethacin 0.5 (wt. %)Geraniol 5.0Eugenol 5.0Vaseline 80.5Solid paraffin 5.0Cetanol 2.0Isopropyl myristate 2.0______________________________________
Preparation Example 2: (Gelated Preparation)
______________________________________Indomethacin 1.0 (wt. %)l-Menthol 3.0Propylene glycol 12.0Carboxyvinyl polymer 1.0(CARBOPOLE 934)Diisopropanol amine 1.0Ethanol 40.0Purified water Balance to 100.0______________________________________
Preparation Example 3: (Liquid Preparation)
______________________________________Indomethacin 2.0 (wt. %)l-Menthol 10.0Ethanol 45.0Aqueous ammonia (10%) 0.2Purified water Balance to 100.0______________________________________
Preparation Example 4: (O/W Cream)
______________________________________Indomethacin 0.8 (wt. %)Camphor 2.0Diisopropyl adipate 20.0Chrotamiton 2.0Glyceryl monostearate 10.0Polyoxyethylene cetyl ether 3.0Methylparaben 0.1Propylparaben 0.1Purified water Balance to 100.0______________________________________
Preparation Example 5: (Plaster)
______________________________________Indomethacin 1.0 (wt. %)Methyl salicylate 2.0l-Menthol 3.0Diethyl sebacate 5.0Raw rubber 40.0Zinc flower 20.0Rosin 29.0______________________________________
This invention now being fully described, it should be noted that various changes and modifications may be made thereto without departing from the spirit or scope of the invention as set forth herein.
|1||*||Chem. Abst., 94 7725q (1981).|
|2||Chem. Abst., 94-7725q (1981).|
|3||*||Chem. Abst., 95 156602(v) (1981).|
|4||*||Chem. Abst., 95 86301d (1981).|
|5||Chem. Abst., 95-156602(v) (1981).|
|6||Chem. Abst., 95-86301d (1981).|
|7||*||Remington s Pharmaceutical Sciences, 16th Ed. 1980, pp. 723 725, 1112.|
|8||Remington's Pharmaceutical Sciences, 16th Ed. 1980, pp. 723-725, 1112.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4931283 *||Mar 26, 1987||Jun 5, 1990||American Home Products Corp. (Del)||Menthol enhancement of transdermal drug delivery|
|US4933184 *||Apr 3, 1987||Jun 12, 1990||American Home Products Corp. (Del)||Menthol enhancement of transdermal drug delivery|
|US5164416 *||May 8, 1991||Nov 17, 1992||Lintec Corporation||Transdermal therapeutic formulation containing a limonene|
|US5700474 *||Sep 19, 1996||Dec 23, 1997||Pmc Specialties Group Inc.||Bird aversion compositions|
|US6280519||Apr 7, 1999||Aug 28, 2001||Exxon Chemical Patents Inc.||Environmentally preferred fluids and fluid blends|
|US6355266||Oct 14, 1998||Mar 12, 2002||Taisho Pharmaceutical Co., Ltd.||Transdermal absorption preparation|
|US6818049||Nov 10, 2000||Nov 16, 2004||Exxonmobil Chemical Patents Inc.||Environmentally preferred fluids and fluid blends|
|US7553865||Jul 22, 2003||Jun 30, 2009||Kowa Company, Ltd.||Indomethacin external preparation|
|US9132103||Sep 3, 2010||Sep 15, 2015||Conopco, Inc.||Disinfecting agent comprising eugenol, terpineol and thymol|
|US9216150 *||Jun 3, 2013||Dec 22, 2015||Plx Pharma Inc.||pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same|
|US9226892||Mar 8, 2013||Jan 5, 2016||Plx Pharma Inc.||pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same|
|US9408870||Nov 17, 2011||Aug 9, 2016||Conopco, Inc.||Oral care composition|
|US20020002933 *||Jul 23, 2001||Jan 10, 2002||Yezrielev Albert Ilya||Environmentally preferred fluids and fluid blends|
|US20050239868 *||Jul 22, 2003||Oct 27, 2005||Hiroyuki Shirai||Indometacin preparation for external use|
|US20140094439 *||Jun 3, 2013||Apr 3, 2014||Plx Pharma Inc.||pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME|
|EP1541144A1 *||Jul 22, 2003||Jun 15, 2005||Kowa Company, Ltd.||Indometacin preparation for external use|
|EP1541144A4 *||Jul 22, 2003||Aug 8, 2007||Kowa Co||Indometacin preparation for external use|
|WO2004089357A2 *||Apr 2, 2004||Oct 21, 2004||Regents Of The University Of Minnesota||Anti-fungal formulation of triterpene and essential oil|
|WO2004089357A3 *||Apr 2, 2004||Dec 29, 2004||Robert M Carlson||Anti-fungal formulation of triterpene and essential oil|
|WO2015090262A1 *||Aug 22, 2014||Jun 25, 2015||Epinamics Gmbh||Dermal and/or transdermal pharmaceutical composition containing a terpenoid compound|
|U.S. Classification||514/420, 514/970|
|International Classification||A61K9/00, A61K31/015, A61K47/06, A61K47/10, A61P29/00, A61P17/00, A61K47/08, A61K31/405, A61K9/06, A61K31/05, A61K9/70|
|Cooperative Classification||Y10S514/97, A61K31/405, A61K47/08, A61K9/7076, A61K47/10, A61K9/0014|
|European Classification||A61K9/00M3, A61K47/10, A61K47/08, A61K31/405, A61K9/70E2B8|
|Jul 17, 1984||AS||Assignment|
Owner name: KOWA CO., LTD. 6-29, NISHIKI 3-CHOME, NAKA-KU, NAG
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:INAGI, TOSHIO;INOUE, MASAYUKI;MURAMATSU, TOYOJIRO;REEL/FRAME:004280/0518
Effective date: 19830414
|Mar 25, 1988||FPAY||Fee payment|
Year of fee payment: 4
|Mar 9, 1992||FPAY||Fee payment|
Year of fee payment: 8
|Mar 7, 1996||FPAY||Fee payment|
Year of fee payment: 12